Johnson & Johnson‘s (NYSE:JNJ) Vision business said today that it closed its acquisition of ophthalmological medical device maker TearScience for an undisclosed amount. Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said. The company won FDA clearance for its office-based treatment […]
J&J Vision to acquire TearScience
Johnson & Johnson‘s (NYSE:JNJ) Vision business said last week that it inked a deal to acquire ophthalmological medical device maker TearScience for an undisclosed amount. Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said. TearScience has won FDA clearance […]
Boston Scientific taps ex-Covidien CFO Dockendorff, Hologic CEO MacMillan for board | Personnel Moves
Toshiba lands 510(k) for latest Aquilon CT scanner | Regulatory Roundup
Toshiba’s (TYO:6502) American medical products division won 510(k) clearance from the FDA for the latest iteration in its Aquilon line of CT scanners.
The Aquilon Prime is designed for healthcare facilities that need to perform a wide variety of advanced clinical examinations with reduced radiation exposure, according to a press release.
Entegrion lands $43.7 million DOD deal | Funding Roundup
Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.
Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.
TearScience Secures $15 Million In Venture Debt Financing From Oxford Finance, LLC And Silicon Valley Bank
TearScience Secures $15 Million In Venture Debt Financing From Oxford Finance, LLC And Silicon Valley Bank
MorrisvilLe, N.C.,—October 3, 2011—TearScience, Inc., a privately-held medical device company, today announced a $15M venture debt financing deal with Oxford Finance LLC and Silicon Valley Bank. The financing supports TearScience’s commercialization efforts of its new, innovative solution for evaluating the eye’s natural tear film and treating evaporative dry eye disease.
Stryker announces new international group president | Personnel Moves
Stryker Corp. (NYSE:SYK) named a new international group president to take over as Andrew Fox-Smith resigned from the position to pursue other career opportunities.
Ramesh Subrahmanian takes the role, effective September 1, after having most recently served as senior VP and president, Asia Pacific, for Merck & Co. (NYSE:MRK).
FDA Final Rule: TearScience’s LipiFlow eyelid thermal pulsation downgraded to Class II
The FDA released a final rule declaring thermal pulsation systems Class II devices, allowing them to bypass the more stringent premarket approval required for Class III devices, in response to a petition from TearScience Inc.
Morrisville, N.C.-based TearScience had petitioned the watchdog agency to classify its LipiFlow eyelid thermal pulsation device, used in treatment of evaporative dry eye, as a Class II device.
Tengion CEO Nichtberger resigns | MassDevice.com Personnel Moves
Tengion Inc. (NSDQ:TNGN) chief scientific officer Timothy Bertram will handle CEO duties while the company searches for a new top executive following the June 30 resignation of Dr. Steven Nichtberger.
Pain management: St. Jude lands first U.S. regulatory clearance for single-point neurostimulation lead delivery system
St. Jude Medical Inc. (NYSE:STJ) announced today that it won U.S. Food & Drug Administration clearance for its Epiducer lead delivery system for neurostimulation in treatment of chronic pain.
The clearance is the first of its kind for the U.S. The device allows physicians to place multiple neurostimulation leads and different types of leads through a single entry point, reducing the need for the multiple incisions typically required.
Hospira lures Allergan president Michael Ball
Hospira Inc. (NYSE:HSP) ended its search for a CEO by luring Allergan Inc. (NYSE:AGN) president Michael Ball to the corner office in San Diego.
Ball, 55, replaces Hospira founder Christopher Begley, who’s staying on as executive chairman.
Ball spent 16 years at Allergan, rising to president after stints leading its pharmaceuticals , global eye care and North American businesses.
